BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast

British Journal of Cancer

Volumn 100, Issue 1, 2009, Pages 123-133

  Millar, E K A ^a,b   Anderson, L R ^a   McNeil, C M ^a,c   O'Toole, S A ^a,d   Pinese, M ^a   Crea, P ^d   Morey, A L ^d   Biankin, A V ^a,e,f   Henshall, S M ^a,e   Musgrove, E A ^a,e   Sutherland, R L ^a,e   Butt, A J ^a,e  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

BAG 1; Breast cancer; Prognosis; Response marker; Tamoxifen sensitivity

Indexed keywords

ANTIESTROGEN; BAG 1 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DISTANT METASTASIS; DRUG SENSITIVITY; FOLLOW UP; GENE EXPRESSION; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION FACTORS;

EID: 58149263068     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604809     Document Type: Article

References (42)

1. Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani SR, Packham G (1999) High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer 81: 1042-1051
2. Caldon CE, Swarbrick A, Lee CS, Sutherland RL, Musgrove EA (2008) The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 68: 3026-3036
3. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12: 2468-2475
4. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376
5. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC (2006) Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 95: 229-233
6. Cutress RI, Townsend PA, Brimmell M, Bateman AC, Hague A, Packham G (2002) BAG-1 expression and function in human cancer. Br J Cancer 87: 834-839
7. Cutress RI, Townsend PA, Sharp A, Maison A, Wood L, Lee R, Brimmell M, Mullee MA, Johnson PW, Royle GT, Bateman AC, Packham G (2003) The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. Oncogene 22: 4973-4982
8. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
10. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410
11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388
12. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144
13. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62
14. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23: 732-740
15. Kermer P, Krajewska M, Zapata JM, Takayama S, Mai J, Krajewski S, Reed JC (2002) Bag1 is a regulator and marker of neuronal differentiation. Cell Death Differ 9: 405-413
16. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91: 3379-3389
17. Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C (2006) A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 12: 1175-1183
18. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239
19. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616
20. Maki HE, Saramaki OR, Shatkina L, Martikainen PM, Tammela TL, van Weerden WM, Vessella RL, Cato AC, Visakorpi T (2007) Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. J Pathol 212: 395-401
21. Miller WR (2007) Do classical oestrogen markers predict for clinical response to endocrine therapy? Breast Cancer Res 9: S19
22. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, Caldas C (2007) A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26: 1507-1516
23. Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y (2008) Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 10: R35
24. Packham G, Brimmell M, Cleveland JL (1997) Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J 328(Part 3): 807-813
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826
26. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer Jr CE, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734
27. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272: 10882-10894
28. R Development Core Team (2007) R: A Langauge and Environment for Statistical Computing. In R Foundation for Statistical Computing: Vienna, Austria
29. Schneikert J, Hubner S, Martin E, Cato AC (1999) A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity. J Cell Biol 146: 929-940
30. Schorr K, Li M, Krajewski S, Reed JC, Furth PA (1999) Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia 4: 153-164
31. Shindoh M, Adachi M, Higashino F, Yasuda M, Hida K, Nishioka T, Ono M, Takayama S, Reed JC, Imai K, Totsuka Y, Kohgo T (2000) BAG-1 expression correlates highly with the malignant potential in early lesions (T1 and T2) of oral squamous cell carcinoma. Oral Oncol 36: 444- 449
32. Sjostrom J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Wist E, Valvere V, Takayama S, Reed JC, Saksela E (2002) The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 8: 811-816
33. Smyth GK (2005) Limma: linear models for microarray data. In Bioinformatics and Computational biology solutions using R and Bioconductor, Gentlemen R, Carey V, Dudoit S, Irizarry R, Huber W (eds), pp 397- 420. Springer: New York
34. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
35. Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, Kochel K, Knee D, Scudiero D, Tudor G, Miller GJ, Miyashita T, Yamada M, Reed JC (1998) Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res 58: 3116-3131
36. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC (1995) Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80: 279-284
37. Tang SC, Beck J, Murphy S, Chernenko G, Robb D, Watson P, Khalifa M (2004) BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma. Breast Cancer Res Treat 84: 203-213
38. Tang SC, Shehata N, Chernenko G, Khalifa M, Wang X (1999) Expression of BAG-1 in invasive breast carcinomas. J Clin Oncol 17: 1710-1719
39. Townsend PA, Dublin E, Hart IR, Kao RH, Hanby AM, Cutress RI, Poulsom R, Ryder K, Barnes DM, Packham G (2002) BAG-i expression in human breast cancer: interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data. J Pathol 197: 51-59
40. Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA, Carter D, Rebbeck TR, Haffty BG, Reed JC (2001) BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol 19: 992-1000
41. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
42. Zeiner M, Niyaz Y, Gehring U (1999) The hsp70-associating protein Hap46 binds to DNA and stimulates transcription. Proc Natl Acad Sci USA 96: 10194-10199